Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 84

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 84
---
; net economic profit (which is operating earnings minus a charge to capital); net income; operating income; sales; sales
growth; gross margin; direct margin; costs; stock price (including but not limited to growth measures and total stockholder return);
operating profit; per period or cumulative cash flow (including but not limited to operating cash flow and free cash flow) or cash flow
return on investment (which equals net cash flow divided by total capital); inventory turns; financial return ratios; market share; balance
sheet measurements such as receivable turnover; improvement in or attainment of expense levels; improvement in or attainment of working
capital levels; debt reduction; strategic innovation; customer or employee satisfaction; the consummation of one or more acquisitions
of a certain size as measured by one or more of the financial criteria listed above; individual objectives; regulatory body approval
for commercialization of a product; implementation or completion of critical projects (including, but not limited to, milestones such
as clinical trial enrollment targets, commencement of phases of clinical trials and completion of phases of clinical trials); and any
combination of the foregoing.

(bb) “”
shall mean this Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as in effect from time
to time.

(cc) “” shall mean the Neurotrope, Inc. 2017 Equity Incentive Plan and the 2013 Equity Incentive Plan, as amended.

(dd) “” shall have the meaning given that term in Section 7(a).

(ee) “”
shall mean a stock appreciation right, as described in Section 9.

(ff) “” shall mean an award of Common Stock, as described in Section 7.

(gg) “” shall mean an award of a phantom unit representing a share of Common Stock, as described in Section 8.

(hh) “” shall have the meaning given that term in Section 4(c).

Section 2. Administration

(a) .
The Plan shall be administered and interpreted by the Committee. The Committee may delegate authority to one or more subcommittees, as
it deems appropriate. Subject to compliance with applicable law and the applicable stock exchange rules, the Board, in its discretion,
may perform any action of the Committee hereunder. To the extent that the Board, the Committee, a subcommittee or the CEO, as described
below, administers the Plan, references in the Plan to the “” shall be deemed to refer to